Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.12 on revenue of $452.1M. Analysts polled by Investing.com anticipated EPS of $-0.1688 on revenue of $439.21M.
Biomarin Pharma shares are up 3.86% from the beginning of the year, still down 38.03% from its 52 week high of $131.95 set on July 21, 2020. They are outperforming the Dow Jones which is up 2.6% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings missed by Roche Holding ADR on February 1, who reported EPS of $1.21 on revenue of $15.88B, compared to forecasts EPS of $1.28 on revenue of $16.45B.
Abbott Labs had beat expectations on January 27 with fourth quarter EPS of $1.45 on revenue of $10.7B, compared to forecast for EPS of $1.35 on revenue of $9.94B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar